Preoperative 68Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-2323
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Preoperative 68Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions ; volume:42 ; number:2 ; day:20 ; month:11 ; year:2017 ; pages:498-505 ; date:2.2018
World journal of surgery ; 42, Heft 2 (20.11.2017), 498-505, 2.2018
- Urheber
-
Norlén, Olov
- Beteiligte Personen und Organisationen
-
Montan, Harald
Hellman, Per
Stålberg, Peter
Sundin, Anders
SpringerLink (Online service)
- DOI
-
10.1007/s00268-017-4364-1
- URN
-
urn:nbn:de:1111-2018030556
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Norlén, Olov
- Montan, Harald
- Hellman, Per
- Stålberg, Peter
- Sundin, Anders
- SpringerLink (Online service)
Ähnliche Objekte (12)
![Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment](/assets/placeholder/searchResultMediaUnknown.png)
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients
Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
Initial clinical experience with 68Ga-DOTA-NOC prepared using 68Ga from nanoceria-polyacrylonitrile composite sorbent-based 68Ge/68Ga generator and freeze-dried DOTA-NOC kits
Impact of segmentation and discretization on radiomic features in 68Ga-DOTA-TOC PET/CT images of neuroendocrine tumor
Standardized image quality for 68Ga-DOTA-TATE PET/CT
18F-FDG PETCT and 68Ga-DOTA PETCT mismatch with in vivo histopathological characterization of low-grade neuroendocrine pancreatic tumor
Assessment of regional pulmonary blood flow using 68Ga-DOTA PET
Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study
Correlation between standardized uptake value of 68Ga-DOTA-NOC positron emission tomography/computed tomography and pathological classification of neuroendocrine tumors
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients
Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
Initial clinical experience with 68Ga-DOTA-NOC prepared using 68Ga from nanoceria-polyacrylonitrile composite sorbent-based 68Ge/68Ga generator and freeze-dried DOTA-NOC kits
Impact of segmentation and discretization on radiomic features in 68Ga-DOTA-TOC PET/CT images of neuroendocrine tumor
Standardized image quality for 68Ga-DOTA-TATE PET/CT
18F-FDG PETCT and 68Ga-DOTA PETCT mismatch with in vivo histopathological characterization of low-grade neuroendocrine pancreatic tumor
Assessment of regional pulmonary blood flow using 68Ga-DOTA PET
Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study
Correlation between standardized uptake value of 68Ga-DOTA-NOC positron emission tomography/computed tomography and pathological classification of neuroendocrine tumors
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients
Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
Initial clinical experience with 68Ga-DOTA-NOC prepared using 68Ga from nanoceria-polyacrylonitrile composite sorbent-based 68Ge/68Ga generator and freeze-dried DOTA-NOC kits
Impact of segmentation and discretization on radiomic features in 68Ga-DOTA-TOC PET/CT images of neuroendocrine tumor
Standardized image quality for 68Ga-DOTA-TATE PET/CT
18F-FDG PETCT and 68Ga-DOTA PETCT mismatch with in vivo histopathological characterization of low-grade neuroendocrine pancreatic tumor
Assessment of regional pulmonary blood flow using 68Ga-DOTA PET
Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study